Skip to content

The impact of intensified blood pressure reduction and standard blood pressure reduction on the prognosis of patients with acute cerebral hemorrhage in high-altitude areas

The impact of intensified blood pressure reduction and standard blood pressure reduction on the prognosis of patients with acute cerebral hemorrhage in high-altitude areas

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600121544
Enrollment
Unknown
Registered
2026-03-31
Start date
2026-03-31
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute cerebral hemorrhage on a plateau

Interventions

Intensive antihypertensive group:In the intensive antihypertensive group, the target is to reduce and maintain systolic blood pressure at 120–139 mmHg within 2 hours after randomizati
Standard antihypertensive group:In the standard antihypertensive group, the target is to reduce and maintain systolic blood pressure at 140–179 mmHg within 2 hours after randomizatio

Sponsors

The Army Specialized Medical Center of the People's Liberation Army of China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years old; 2. Acute spontaneous intracerebral hemorrhage (confirmed by CT), with symptoms appearing within 6 hours of seeking medical attention; 3. The patient's systolic blood pressure (SBP) is between 150 and 220 mmHg; 4. The onset occurred in an altitude environment (altitude >= 1500 meters); 5. The doctor believes that the patient is likely to start receiving intensive blood pressure reduction treatment within 2 hours after randomization; 6. The informed consent form has been obtained and signed.

Exclusion criteria

Exclusion criteria: 1. Secondary cerebral hemorrhage that has been clearly identified, including: rupture of cerebral aneurysms, arteriovenous malformations, brain tumors, trauma, and coagulation dysfunction; 2. The patient has a clear plan for immediate surgery to remove the hematoma; 3. Severe complications (such as end-stage renal failure, heart failure, active bleeding disorders, hypoxic respiratory failure); 4. Expected survival time 2); 6. Unable to monitor SpO2 or unable to obtain basic life support; 7. Presence of indications for blood pressure reduction, such as clear contraindications to commonly used antihypertensive drugs or hypersensitivity to antihypertensive drugs; 8. Pregnancy; 9. Participating in other clinical studies; 10. Existing conditions that may affect the subject's compliance, or the researchers consider other reasons as not suitable for the clinical trial.

Design outcomes

Primary

MeasureTime frame
Adverse event (AE);Glasgow Coma Scale (GCS);National Institutes of Health Stroke Scale (NIHSS);Laboratory examinations include, but are not limited to, blood routine, liver and kidney function, electrolytes, and coagulation profile.;Modified Rankin Scale (mRS);Medical history taking;EuroQOL score: EQ-5D, European Quality of Life-5 Dimensions questionnaire score;Unenhanced CT scan of the head;Office blood pressure;Patient treatment course: including medications, operation records, etc.;Vital signs;

Secondary

MeasureTime frame
Electrocardiogram;

Countries

China

Contacts

Public ContactZeng Chunyu

The Army Specialized Medical Center of the People's Liberation Army of China

chunyuzeng01@163.com+86 23 6872 9501

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026